Marinus Pharmaceuticals (MRNS) has risen sharply, recording gains of 10.3% in the past 4 weeks. However, the stock has corrected -18.02% in the past 1 week, providing a good buying opportunity on dips. On a relative basis, the stock has outperformed the S&P 500 by 10.9% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week.
The stock has recorded a 20-day Moving Average of 0.74% and the 50-Day Moving Average is 7.84%.The 200 Day SMA reached 55.18%
Marinus Pharmaceuticals (NASDAQ:MRNS): The stock opened in the green at $2 on Friday, but the bulls found it difficult to push the prices higher. The stock reached a high of $2 and a low of $1.75 for the day. The stock did not find buyers even at the lows and closed at $1.82 recording a loss of -9.00%. 2,349,878 shares exchanged hands during the trading day. The stock had closed at $1.82 in the previous days trading.
Marinus Pharmaceuticals (MRNS) : The most positive equity analysts on Marinus Pharmaceuticals (MRNS) expects the shares to touch $3, whereas, the least positive believes that the stock will trade at $2 in the short term. The company is covered by 2 Wall Street Brokerage Firms. The average price target for shares are $2.5 with an expected fluctuation of $0.71 from the mean.
Marinus Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. The Company focuses on developing and commercializing neuropsychiatric therapeutics. Its clinical stage product candidate, ganaxolone, is a small molecule that is a synthetic analog of allopregnanolone, which is an endogenous neurosteriod known for its anticonvulsive and antianxiety activity. Ganaxolone was rationally designed to unlock the potential for chronic neurosteroid therapy through modulation of the GABAA receptor. The Companys indication for ganaxolone is as an adjunctive, or add-on, therapy for the treatment of partial, also known as focal, onset seizures in adults with epilepsy. Phase III randomized multinational clinical trial by utilizing the Companys oral capsules. The Company has completed a Phase II clinical trial in 147 patients with focal onset seizures.